Can donor stem cells help intestinal transplant patients ditch heavy meds?

NCT ID NCT04804891

Recruiting now Disease control Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether giving intestinal transplant patients stem cells from their organ donor can safely allow them to take less immunosuppression medication. The goal is to reduce the high risk of infections and cancers caused by these drugs. Six participants will receive a single infusion of donor bone marrow stem cells, and researchers will monitor for side effects like graft-versus-host disease and how well the transplant survives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor bone marrow stem cells (CD34+ cells)
What this could lead to: If successful, this approach could allow intestinal transplant patients to take less immunosuppression medication, reducing their risk of serious infections and certain cancers while still preventing organ rejection.
What could go wrong: This is a very early, small phase 1 trial with only 6 participants, so results may not apply broadly. There is a risk of graft-versus-host disease (GVHD), where donor cells attack the recipient's body, and the strategy may not effectively reduce immunosuppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTESTINAL FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic intestinal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTESTINAL TRANSPLANTATION

Contacts and locations

Locations

Columbia University Irving Medical Center/NYP
RECRUITING

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.